Clinical Guidance Panels
The pan-Canadian Oncology Drug Review (pCODR) relies on the medical expertise of its Clinical Guidance Panels to ensure that the review of each cancer drug draws from the most important, relevant, and current clinical information. There are 13 Clinical Guidance Panels, each offering expertise in a specific tumour site:
- Breast Cancer
- Endocrine Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Lung Cancer
- Neurological Cancer
- Skin and Melanoma
In cases where a drug is used to treat a tumour not addressed by any of the 13 Clinical Guidance Panels, pCODR will form an additional expert panel for the duration of the review.
For each pCODR review, the relevant Panel generates a Clinical Guidance document that is submitted to pCODR's Expert Review Committee (pERC). The document is used as part of pERC's deliberative process to make funding recommendations.
The panel may also provide input on a variety of issues, including current clinical practices, new approaches or literature related to tumour management, targeted molecular testing, and other clinical factors that may affect the drug's application for treating a specific tumour type.
- Clinical Guidance Panel Terms of Reference
Last updated: November 2018
Each of the 11 Clinical Guidance Panels consists of three to five cancer specialists, recognized as experts for that specific tumour site, who apply for membership to the panel. Panel members must have experience in developing clinical guidelines for cancer treatment.
The final selection of panel members is made jointly by the Director, pCODR and the Chair of pERC.
Each Clinical Guidance Panel has a Lead who is appointed by the Director, pCODR. The Panel Lead is generally the lead author for the guidance document submitted to pERC and serves as the main contact for further information.
Economic Guidance Panel
pCODR relies on the expertise of its Economic Guidance Panels to assess the economic evidence provided when a drug is submitted to pCODR.
For each pCODR review, a Panel generates an Economic Guidance report that is submitted to pERC. The document is used as part of pERC's deliberative process to make funding recommendations.
Input by the Economic Guidance Panels may include: qualitative and quantitative assessments of the submitted economic evidence; suggestions for improving the economic evidence submitted; and suggestions for national collaboration to improve the quality of economic evidence that can be used to further support decision-making.
- pCODR Economic Guidance Panels Terms of Reference
Last updated: November 2018
The composition of each Economic Guidance Panel is tailored to the requirements of the drug submission under consideration. For each review, pCODR selects from a roster of panel members with expertise in health economics or clinical epidemiology. All panel members must have experience in applied health technology assessment.
Panel members are selected by the Director, pCODR and the Chair of pERC.
Each Economic Guidance Panel has a Lead who is appointed by the Director, pCODR. The Panel Lead is generally the lead author for the guidance document submitted to pERC and serves as the main contact for further information.
Members of all Guidance Panels (Clinical/Economic)
Members of all panels must comply with the following:
- pCODR Conflict of Interest (COI) Guidelines Last updated: April 10, 2015
- pCODR Code of Conduct Last updated: March 2011
- pCODR Code of Communications Last updated: March 2011
- pCODR Conflict of Interest (COI) Disclosure Form Last updated: April 10, 2015
Of note, all pCODR participants are required to follow the pCODR Code of Conduct, which specifies that participants:
- shall be independent and impartial
- shall not be influenced by self-interest, outside pressure, political considerations, or fear of criticism
- shall not allow past or existing financial, business, professional, family, or social relationships or responsibilities to influence their conduct or judgment.
Please help us in supporting panel members to meet their obligations under the Code of Conduct by refraining from direct contact with them in their capacity as pCODR participants. All questions and/or correspondence regarding the pCODR process should be directed to Alexandra Chambers, Director, pCODR at email@example.com.
The following individuals are involved with pCODR Guidance Panels, or were involved with a review within the past two years.
|Abha Gupta | COI||Margot Burnell | COI|
|Adam Raymakers | COI||Matthew (Matt) Cheung | COI|
|Andrew G. Scarfe | COI||Michael Crump | COI|
|Andrew Daly | COI||Michael Smylie | COI|
|Anna Tinker | COI||Murray Krahn | COI|
|Anthony Reiman | COI||Nadia Coakley | COI|
|Carlo Marra | COI||Natasha Leighl | COI|
|Catherine Moltzan | COI||Parneet Cheema | COI|
|Christian Kollmannsberger | COI||Patricia Tang | COI|
|Christine Brezden-Masley | COI||Petros Pechlivanoglou | COI|
|Christopher Lee | COI||Prafull Ghatage | COI|
|Cindy Quinton | COI||Ronald (Ron) Burkes | COI|
|Craig Earle | COI||Sara Kuruvilla | COI|
|Dan Cooper | COI||Scott Ernst | COI|
|Daniel Rayson | COI||Scott Laurie | COI|
|Dean Ruether | COI||Sharlene Gill | COI|
|Dominika Wranik | COI||Shawn Bugden | COI|
|Don Husereau | COI||Simron Singh | COI|
|Don Morris | COI||Siu-Chung (Quincy) Chu | COI|
|Doug Coyle | COI||Sonal Gandhi | COI|
|Eric Winquist | COI||Srikala Sridhar | COI|
|Eva Tsakonas | COI||Stella Chen | COI|
|Gary Pansegrau | COI||Stephen Chia | COI|
|Georg Bjarnason | COI||Sukhbinder (Bindi) Dhesy-Thind | COI|
|Greg Zaric | COI||Susan Dent | COI|
|Jaclyn Beca | COI||Tania Conte | COI|
|Jason Hart | COI||Tien Le | COI|
|Jeff Lipton | COI||Tricia Waldron | COI|
|Kelvin Chan | COI||Vera Hirsh | COI|
|Laurel Kovacic | COI||Vishal Kukreti | COI|
|Laurie Elit | COI||Vivien Bramwell | COI|
|Lianne Barnieh | COI||Wan Ki (Gavin) Wong | COI|
|Lisa Hicks | COI||Yasmin Rahim | COI|
|Louise Bordeleau | COI||Yoo-Joung (Yooj) Ko | COI|
|Marc Kerba | COI|